ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing and commercializing small molecule drugs targeting central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company has a primary focus on addressing unmet medical needs associated with conditions such as Parkinson's disease, Alzheimer's disease, and schizophrenia. Its leading product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions linked to Parkinson's disease psychosis. ACADIA is advancing the development of pimavanserin for additional indications, including dementia-related psychosis and as an adjunctive treatment for schizophrenia, both currently in Phase III clinical trials. Furthermore, the company is exploring its potential use in major depressive disorder. ACADIA operates two wholly owned subsidiaries in Europe, enhancing its global footprint and research capabilities.
CerSci Therapeutics Inc. is a Dallas-based firm dedicated to developing non-opioid alternatives for the treatment of acute postoperative and chronic neuropathic pain, including conditions like diabetic and chemotherapy-induced pain. Founded in 2015, the company is advancing its lead drug candidate, CT-044, which has received FDA approval to proceed with a Phase I clinical trial to assess its safety and tolerability. CT-044 is a small molecule designed to decompose harmful radical species, specifically targeting peroxynitrite and hydrogen peroxide, and aims to provide a novel solution to pain management amid the ongoing opioid crisis. CerSci Therapeutics operates as a subsidiary of ACADIA Pharmaceuticals Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.